Back to Journals » Biologics: Targets and Therapy » Volume 6
Clinical use of biologics in vasculitis syndromes
Authors Paroli M
Received 31 August 2012
Accepted for publication 22 September 2012
Published 25 October 2012 Volume 2012:6 Pages 371—378
DOI https://doi.org/10.2147/BTT.S37537
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Marino Paroli
Division of Clinical Immunology and Rheumatology, Department of Biotechnology and Medical-Surgical Sciences, Sapienza University of Rome, Italy
Abstract: Vasculitis syndromes are relative rare conditions but can cause significant mortality and morbidity if not treated adequately. Recent advances in immunosuppressant therapy have radically changed the course of these diseases. However, the standard therapy is not always well tolerated by patients, and some cases are refractory to treatment. New therapeutic possibilities have emerged with the use of so-called "biologics," a new class of genetically engineered drugs used for inflammatory rheumatic diseases, including rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. In the present review, summarized are the most recent data on the efficacy and safety of biologics in the treatment of vasculitis syndromes that cannot be treated with standard therapy.
Keywords: anti-TNF-alpha, rituximab, tocilizumab, vasculitides
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.